Navigation Links
Btk in Medical News

Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results

...2009 was primarily due to reduced personnel expenses, reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, btk and Factor VIIa Inhibitor programs. Pharmacyclics also reported its financial results for the nine months ended March 31, 2009. The net loss for...

Pharmacyclics Reports Third Quarter 2008 Financial Results

...uring expenses associated with the Company's HDAC, btk and Factor VIIa inhibitor programs. Pharmacyclic...applications for our Factor VIIa inhibitor and our btk inhibitor," said Richard A. Miller, M.D., presiden...ns relating to the company's HDAC, Factor VIIa and btk programs were made at the American Association...
Btk in Medical Technology

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

SUNNYVALE, Calif., April 13 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine ...

Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma

SUNNYVALE, Calif., June 9 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal mod...

Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases

SAN DIEGO and SUNNYVALE, Calif., April 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented results from its preclinical program evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in B-cell receptor (BCR) modulated d...

Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.

...ss inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) currently in a Phase I clinical trial and targeting B-cell related oncology applications; a btk inhibitor in advanced preclinical testing (PCI-45261) targeting autoimmune and allergic indications; and an HDAC-8 inhibitor (PCI-34051) for autoimmun...

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

..., researchers tested the effects of Pharmacyclics' btk inhibitor, PCI-31523, on a variety of B cell recep...tion results in uncontrolled B-cell proliferation. btk is a tyrosine kinase inside B-cells that plays an ... role in B-cell activation. Drugs that can inhibit btk may prevent B-cell activation and therefore may pl...
Btk in Biological News

Patients now surviving once-fatal immune disease

...were quite surprised at how well these patients are doing with the proper care." XLA is a rare disease that is inherited through a mutation in the btk gene on the X-chromosome--one of the two types of sex chromosomes. Males with this disease have very low levels of infection-fighting proteins called ...
Btk in Biological Technology

Pharmacyclics, Inc. Rights Offering Oversubscribed

...d autoimmune diseases. With the announcement of today's offering, we have the capital to drive our programs forward, particularly PCI 32765, our novel btk Inhibitor, and PCI 24783, our Factor VIIa Inhibitor, to several inflection points. We are committed to driving shareholder value and look forward to u...

Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results

...reduced personnel expenses due to lower headcount and reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, btk and Factor VIIa inhibitor programs. Pharmacyclics also reported its financial results for the six months ended December 31, 2008. The net loss...

Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results

...reduced personnel expenses due to lower headcount and reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, btk and Factor VIIa inhibitor programs. As of September 30, 2008, the company's cash, cash equivalents and marketable securities totaled $12.5 million c...

Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results

...nteers with our Factor VIIa inhibitor, PCI-27483, in the fourth quarter of calendar 2008. * Plan to initiate a Phase 1 trial with our oral btk inhibitor, PCI-32765, in patients with recurrent B-cell lymphoma in the fourth quarter of calendar 2008. This study is designed to eval...

Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting

...ter presentation: Levels of tonic BCR signaling predict response to the btk inhibitor PCI-32765 Abstract #2396: 8:00 a.m. - 12:00 p.m. Presente...ata on our HDAC inhibitor, other presentations describe our Factor VIIa and btk inhibitors, which we anticipate will enter clinical testing later this year...
Btk in Biological Definition

Oncogene

...ceptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), etc. Cytoplasmic tyrosine kinases like the Src-family, Syk-ZAP-70 family and btk family of tyrosine kinases. Regulatory GTPases , for example, the Ras protein . Cytoplasmic Serine / Threonine kinases and their regula...
Other Tags
(Date:9/22/2014)... Severe weather can occur with little warning, so it’s ... of National Preparedness Month, Amica Insurance is offering the ... unexpected:, , Build an emergency supply kit. It ... gallon of water per person per day for at least 72 ... includes pets so your family knows what to do and where ...
(Date:9/22/2014)... County, NY (PRWEB) September 22, 2014 ... joined the Department of Surgery at the Icahn School ... Sinai Doctors New York Group for Plastic Surgery gives ... Valley access to a team of world-renowned plastic surgeons ... Additionally, C. Andrew Salzberg, MD, who led NYGPS, was ...
(Date:9/22/2014)... -- Metformin, a drug commonly used to treat diabetes, ... hormone (TSH) among patients with an underactive thyroid, a ... TSH levels may be associated with heart problems and ... in this study. Among those in the study ... of low levels of thyroid-stimulating hormone per year compared ...
(Date:9/22/2014)... 22, 2014 The report segments ... end user, and geography. The equipment segment accounted ... equipment market, by product. However, the accessories segment ... in the forecast period, owing to the rising ... stimulation and ultrasound segments are the fastest-growing segments ...
(Date:9/22/2014)... step for securing critical information systems, such as ... have created a new approach to computer security ... a terminal and automatically logs them out when ... to use their terminal. , Dartmouth,s Trustworthy ... their findings at the IEEE Symposium ...
Breaking Medicine News(10 mins):Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3
(Date:9/19/2014)... of fairness did not evolve for the sake of ... benefits of continued cooperation, so say Frans de Waal, ... article about inequity aversion (IA), which is defined as ... published in Science . , Their conclusion ... studies to address their hypothesis that it is the ...
(Date:9/19/2014)... Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: NXTD ... focused on the growing m-commerce market, updates the "Wocket in Your ... the lightweight and light middleweight weight classes, Vinny Pazienza ... announced that Game of Thrones actor Ciaran Hinds ... Children star Katey Sagal have been cast in ...
(Date:9/18/2014)... - Washington State University researchers have developed a unique ... power waste cleanup in rural areas. , The ... an inexpensive and quick way to clean up waste ... while reducing pollution. , Professor Haluk Beyenal and ... Engineering and Architecture discuss the system in the online ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Researchers develop unique waste cleanup for rural areas 2
Other Contents